SCHEMBL24370751

SCHEMBL24370751

COc1ccc(C(=O)/C=C/N(C)C)c(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.62
MAPT P10636 6/20 0.59
HPGD P15428 3/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 4/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
ALOX12 P18054 1/20 0.59
CPS1 P31327 4/20 0.53
TDP1 Q9NUW8 1/20 0.49
CTSL P07711 1/20 0.48
ABCG2 Q9UNQ0 3/20 0.47
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 1/20 0.46
MAPK1 P28482 2/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
USP2 O75604 1/20 0.46
TLR9 Q9NR96 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450819 1.00 GAA (0.62) GAAMAPTHPGDALDH1A1LMNA
SCHEMBL2107584 0.84 ABCG2 (0.65) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL30904861 0.84 ABCG2 (0.65) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL12722743 0.84 ABCG2 (0.67) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL5808359 0.84 ABCG2 (0.67) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL29246799 0.84 MAPT (0.60) GAAMAPTHPGDALDH1A1LMNA
SCHEMBL5808361 0.84 ABCG2 (0.67) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL2107582 0.84 ABCG2 (0.65) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL29690463 0.84 ABCG2 (0.65) MAPTHPGDALDH1A1LMNAMEN1
SCHEMBL12722749 0.84 ABCG2 (0.65) MAPTHPGDALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
EP-4232451-A1 CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2023-08-30 EP disclosed
CN-116348468-A CFTR modulator compounds, compositions and uses thereof 日东制药株式会社 2023-06-27 CN disclosed
WO-2023067388-A1 USES OF CFTR MODULATOR AND/OR PDE4 INHIBITOR COMPOUNDS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-04-27 WO disclosed
WO-2022084741-A1 CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-04-28 WO disclosed
WO-2022084741-A1 CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators PDE4A, PDE4B, PDE5A GAA 447/4885MAPT 4661/4885HPGD 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.